Introduction: Focal acantholytic dyskeratosis is a distinctive histological pattern first described by Ackerman in 1972, consisting of focal suprabasal clefts in the epidermis and dyskeratotic cells at all levels of the epidermis with hyperkeratosis and parakeratosis. The first case of subungual acantholytic dyskeratosis acanthoma (ADA) was reported in 1990. This subungual variant is a very rare entity. Case Presentation: A 63-year-old female patient consulted for a longitudinal erythronychia (LE) associated with distal onycholysis. Dermoscopy showed LE with a few splinter hemorrhages, with localized hyperkeratosis and thinning of the nail plate at the free edge. Histopathology confirmed the diagnosis of ADA. Conclusion: ADA is a rare tumor that could mimic various inflammatory or neoplastic conditions. To our knowledge, this is the eighth reported case in the literature. This uncommon entity could mimic various inflammatory or neoplastic conditions.

Journal Section:
Novel Insights from Clinical Practice
Keywords:
Nail, Acanthoma, Acantholytic dyskeratotic acanthoma, Longitudinal erythronychia
1.
Isonokami
M
,
Higashi
N
.
Focal acantholytic dyskeratosis: a case report in nail lesion
.
Hifu
.
1990
;
32
:
507
–
10
.
Google Scholar
 
2.
Omulecki
A
,
Lesiak
A
,
Narbutt
J
,
Woźniacka
A
,
Piekarski
J
,
Biernat
W
.
Plaque form of warty dyskeratoma: acantholytic dyskeratotic acanthoma
.
J Cutan Pathol
.
2007
;
34
(
6
):
494
–
6
.
Google Scholar
Crossref
Search ADS
PubMed
 
3.
Ko
CJ
,
Barr
RJ
,
Subtil
A
,
McNiff
JM
.
Acantholytic dyskeratotic acanthoma: a variant of a benign keratosis
.
J Cutan Pathol
.
2008
;
35
(
3
):
298
–
301
.
Google Scholar
Crossref
Search ADS
PubMed
 
4.
Ng
J
,
Harvey
NT
,
von Nida
J
,
Wood
BA
.
Subungual acantholytic dyskeratotic acanthoma: an unusual cause of longitudinal erythronychia
.
Pathology
.
2018
;
50
(
4
):
482
–
4
.
Google Scholar
Crossref
Search ADS
PubMed
 
5.
Carlioz
V
,
Balme
B
,
Depaepe
L
,
Thomas
L
.
Dermoscopy of subungual acantholytic dyskeratotic acanthoma
.
Clin Exp Dermatol
.
2020
;
45
(
3
):
355
–
6
.
Google Scholar
Crossref
Search ADS
PubMed
 
6.
Chung
CH
,
Lin
YC
,
Wu
YH
.
Subungual acantholytic dyskeratotic acanthoma: a case report
.
Dermatol Sin
.
2023
;
41
(
1
):
60
.
Google Scholar
 
7.
Sass
U
,
Kolivras
A
,
Richert
B
,
Moulonguet
I
,
Goettmann-Bonvallot
S
,
Anseeuw
M
, et al.
Acantholytic tumor of the nail: acantholytic dyskeratotic acanthoma
.
J Cutan Pathol
.
2009
;
36
(
12
):
1308
–
11
.
Google Scholar
Crossref
Search ADS
PubMed
 
© 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.